SCHEMBL6705127

SCHEMBL6705127

Cn1c2c(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)C=C(C(=O)O)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
ALDH1A1 P00352 3/20 0.36
HTT P42858 1/20 0.36
P2RX3 P56373 1/20 0.35
TSHR P16473 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
GRIN1 Q05586 3/20 0.35
GRIN2B Q13224 3/20 0.35
RAB9A P51151 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
DPP4 P27487 1/20 0.34
PKM P14618 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
MMP13 P45452 1/20 0.33
SLC22A8 Q8TCC7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6681187 0.83 PTGS1 (0.35) PTGS1PTGS2ALDH1A1P2RX3TSHR
SCHEMBL6679104 0.82 PTGS1 (0.36) PTGS1PTGS2ALDH1A1P2RX3TSHR
SCHEMBL6692406 0.82 ALDH1A1 (0.36) PTGS1PTGS2ALDH1A1P2RX3TSHR
SCHEMBL6663839 0.82 ALDH1A1 (0.36) PTGS1PTGS2ALDH1A1HTTP2RX3
SCHEMBL6704891 0.78 MMP13 (0.42) PTGS1PTGS2ALDH1A1TSHRGRIN1
SCHEMBL6704264 0.76 NPSR1 (0.36) ALDH1A1HTTTSHRGRIN1GRIN2B
SCHEMBL6683778 0.74 PARP1 (0.39) PTGS1PTGS2ALDH1A1TSHRL3MBTL1
SCHEMBL6703218 0.72 NPSR1 (0.39) PTGS1PTGS2HTTP2RX3PTGDR2
SCHEMBL6681696 0.72 CLPP (0.39) ALDH1A1HTTTSHRL3MBTL1RAB9A
SCHEMBL6466057 0.71 MMP13 (0.57) PTGS1PTGS2PTGDR2KDM4EMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US claimed
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 PTGS1 41/4885PTGS2 217/4885ALDH1A1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.